166 related articles for article (PubMed ID: 23519958)
21. Safety and efficacy of total body irradiation, cyclophosphamide, and cytarabine as a conditioning regimen for allogeneic hematopoietic stem cell transplantation in patients with acute lymphoblastic leukemia.
Mori T; Aisa Y; Kato J; Yamane A; Nakazato T; Shigematsu N; Okamoto S
Am J Hematol; 2012 Apr; 87(4):349-53. PubMed ID: 22290459
[TBL] [Abstract][Full Text] [Related]
22. Therapy with imatinib mesylate (Glivec) preceding allogeneic stem cell transplantation (SCT) in relapsed or refractory Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL).
Wassmann B; Pfeifer H; Scheuring U; Klein SA; Gökbuget N; Binckebanck A; Martin H; Gschaidmeier H; Hoelzer D; Ottmann OG
Leukemia; 2002 Dec; 16(12):2358-65. PubMed ID: 12454740
[TBL] [Abstract][Full Text] [Related]
23. The incidence of testicular recurrence in boys with acute leukemia treated with total body and testicular irradiation and stem cell transplantation.
Quaranta BP; Halperin EC; Kurtzberg J; Clough R; Martin PL
Cancer; 2004 Aug; 101(4):845-50. PubMed ID: 15305418
[TBL] [Abstract][Full Text] [Related]
24. Growth hormone treatment impact on growth rate and final height of patients who received HSCT with TBI or/and cranial irradiation in childhood: a report from the French Leukaemia Long-Term Follow-Up Study (LEA).
Isfan F; Kanold J; Merlin E; Contet A; Sirvent N; Rochette E; Poiree M; Terral D; Carla-Malpuech H; Reynaud R; Pereira B; Chastagner P; Simeoni MC; Auquier P; Michel G; Deméocq F
Bone Marrow Transplant; 2012 May; 47(5):684-93. PubMed ID: 21725370
[TBL] [Abstract][Full Text] [Related]
25. Long-term outcome and quality of life of patients who are alive and in complete remission more than two years after allogeneic and syngeneic stem cell transplantation.
Worel N; Biener D; Kalhs P; Mitterbauer M; Keil F; Schulenburg A; Höcker P; Dieckmann K; Fischer G; Rosenmayr A; Linkesch W; Hinterberger W; Lechner K; Greinix HT
Bone Marrow Transplant; 2002 Nov; 30(9):619-26. PubMed ID: 12407437
[TBL] [Abstract][Full Text] [Related]
26. Superiority of allogeneic hematopoietic stem-cell transplantation compared with chemotherapy alone in high-risk childhood T-cell acute lymphoblastic leukemia: results from ALL-BFM 90 and 95.
Schrauder A; Reiter A; Gadner H; Niethammer D; Klingebiel T; Kremens B; Peters C; Ebell W; Zimmermann M; Niggli F; Ludwig WD; Riehm H; Welte K; Schrappe M
J Clin Oncol; 2006 Dec; 24(36):5742-9. PubMed ID: 17179108
[TBL] [Abstract][Full Text] [Related]
27. Risk factors for lower health-related QoL after allogeneic stem cell transplantation in children.
Löf CM; Forinder U; Winiarski J
Pediatr Transplant; 2007 Mar; 11(2):145-51. PubMed ID: 17300493
[TBL] [Abstract][Full Text] [Related]
28. Outpatient reduced-intensity allogeneic stem cell transplantation for patients with refractory or relapsed lymphomas compared with autologous stem cell transplantation using a simplified method.
Gutiérrez-Aguirre CH; Ruiz-Argüelles G; Cantú-Rodríguez OG; González-Llano O; Jaime-Pérez JC; García-Rodríguez F; López-Otero A; Herrera-Garza JL; Gómez-Almaguer D
Ann Hematol; 2010 Oct; 89(10):1045-52. PubMed ID: 20490794
[TBL] [Abstract][Full Text] [Related]
29. Allogeneic hematopoietic stem cell transplantation in patients with diffuse large B cell lymphoma relapsed after autologous stem cell transplantation: a GITMO study.
Rigacci L; Puccini B; Dodero A; Iacopino P; Castagna L; Bramanti S; Ciceri F; Fanin R; Rambaldi A; Falda M; Milone G; Guidi S; Martelli MF; Mazza P; Oneto R; Bosi A;
Ann Hematol; 2012 Jun; 91(6):931-9. PubMed ID: 22245922
[TBL] [Abstract][Full Text] [Related]
30. High health-related quality of life among long-term survivors of childhood acute lymphoblastic leukemia.
Harila MJ; Salo J; Lanning M; Vilkkumaa I; Harila-Saari AH
Pediatr Blood Cancer; 2010 Aug; 55(2):331-6. PubMed ID: 20582965
[TBL] [Abstract][Full Text] [Related]
31. Poor outcome for children and adolescents with progressive disease or relapse of lymphoblastic lymphoma: a report from the berlin-frankfurt-muenster group.
Burkhardt B; Reiter A; Landmann E; Lang P; Lassay L; Dickerhoff R; Lakomek M; Henze G; von Stackelberg A
J Clin Oncol; 2009 Jul; 27(20):3363-9. PubMed ID: 19433688
[TBL] [Abstract][Full Text] [Related]
32. Quality of life assessment in hematopoietic stem cell transplantation performed on thalassemia major patients.
Uygun V; Tayfun F; Akcan M; Karasu GT; Kupesiz A; Hazar V; Yeşilipek A
Pediatr Hematol Oncol; 2012 Aug; 29(5):461-71. PubMed ID: 22712884
[TBL] [Abstract][Full Text] [Related]
33. The outcome of allogeneic hematopoietic stem cell transplants without total body irradiation in pediatric patients with acute lymphoblastic leukemia: single centre experience.
Hamidieh A; Kargar M; Jahani M; Alimoghaddam K; Bahar B; Mousavi SA; Iravani M; Jalali A; Jalili M; Ghavamzadeh A
J Pediatr Hematol Oncol; 2012 Mar; 34(2):101-7. PubMed ID: 22367385
[TBL] [Abstract][Full Text] [Related]
34. [Imatinib combined with modified hyper-CVAD/MA followed by allogeneic hematopoietic stem cell transplantation in CR1 as the front-line therapy for adult Ph(+) acute lymphoblastic leukemia].
Huang J; Zou DH; Fu MW; Li ZJ; Xu Y; Zhao YZ; Qi JY; Qiu LG
Zhonghua Xue Ye Xue Za Zhi; 2011 Oct; 32(10):673-8. PubMed ID: 22339825
[TBL] [Abstract][Full Text] [Related]
35. Donor-specific differences in long-term outcomes of myeloablative transplantation in adults with Philadelphia-negative acute lymphoblastic leukemia.
Lee S; Chung NG; Cho BS; Eom KS; Kim YJ; Kim HJ; Min CK; Cho SG; Kim DW; Lee JW; Min WS; Park CW; Kim CC
Leukemia; 2010 Dec; 24(12):2110-9. PubMed ID: 20882049
[TBL] [Abstract][Full Text] [Related]
36. Autologous or allogeneic stem cell transplantation in patients with Waldenstrom's macroglobulinemia.
Anagnostopoulos A; Hari PN; Pérez WS; Ballen K; Bashey A; Bredeson CN; Freytes CO; Gale RP; Gertz MA; Gibson J; Goldschmidt H; Lazarus HM; McCarthy PL; Reece DE; Vesole DH; Giralt SA
Biol Blood Marrow Transplant; 2006 Aug; 12(8):845-54. PubMed ID: 16864055
[TBL] [Abstract][Full Text] [Related]
37. Comparison of intensive chemotherapy, allogeneic or autologous stem cell transplantation as post-remission treatment for adult patients with high-risk acute lymphoblastic leukemia. Results of the PETHEMA ALL-93 trial.
Ribera JM; Oriol A; Bethencourt C; Parody R; Hernández-Rivas JM; Moreno MJ; del Potro E; Torm M; Rivas C; Besalduch J; Sanz MA; Ortega JJ;
Haematologica; 2005 Oct; 90(10):1346-56. PubMed ID: 16219571
[TBL] [Abstract][Full Text] [Related]
38. Allogeneic hemopoietic stem cell transplants for patients with relapsed acute leukemia: long-term outcome.
Bacigalupo A; Lamparelli T; Gualandi F; Occhini D; Bregante S; Raiola AM; Ibatici A; di Grazia C; Dominietto A; Piaggio G; Podesta M; Bruno B; Lombardi A; Frassoni F; Viscoli C; Sacchi N; Van Lint MT
Bone Marrow Transplant; 2007 Mar; 39(6):341-6. PubMed ID: 17277788
[TBL] [Abstract][Full Text] [Related]
39. Utility of cranial boost in addition to total body irradiation in the treatment of high risk acute lymphoblastic leukemia.
Alexander BM; Wechsler D; Braun TM; Levine J; Herman J; Yanik G; Hutchinson R; Pierce LJ
Int J Radiat Oncol Biol Phys; 2005 Nov; 63(4):1191-6. PubMed ID: 15978741
[TBL] [Abstract][Full Text] [Related]
40. Longitudinal health-related quality of life outcomes and related factors after pediatric SCT.
Barrera M; Atenafu E; Hancock K
Bone Marrow Transplant; 2009 Aug; 44(4):249-56. PubMed ID: 19234504
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
